Form D · Biotechnology

Ashvattha Therapeutics, Inc.

Redwood City, CA · CIK 0001668528

Offering snapshot reported Dec 30, 2022 · SEC filing

Reported sold
$60.2M
Indefinite offering
Investors reported
107
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 16, 2021
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$30.1M$60.2MMay 3, 2021: $7,725,000.00May 3, 2021Dec 30, 2022: $60,181,969.00Dec 30, 2022

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$7,725,000 → $60,181,969

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 30, 2022Amendment$60,181,969$52,456,969vs May 3, 2021107SEC filing
May 3, 2021Initial$7,725,000No comparisonNot reportedSEC filing
May 31, 2019Initial$250,000No comparison1SEC filing
Jan 7, 2019Initial$199,999No comparison1SEC filing
Jun 11, 2018Initial$400,000No comparison1SEC filing
Jun 7, 2016Initial$37,400No comparison1SEC filing
Mar 4, 2016Initial$300,000No comparison4SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$1.42M (estimated)
Finders' fees
$0
Form D file number
021-397980
The offering is ongoing.
GP Numenkari Inc. is entitled to 8% of the gross proceeds of its portion of the offering and warrants amounting to 8% of the gross proceeds of its portion of the offering.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
GP Numenkari Inc.153480

Source: Form D, filed Dec 30, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jeffrey Cleland Director, Executive
Justin Hanes Executive
Sujatha Kannan Director
George Montgomery Director
Kannan Rangaramanujam Director, Executive
Barbara Slusher Director
Jay Zaveri Director
Yuhang Zhao Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1235 Radio Road, Suite 200
Redwood City, CA, 94065